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Abstract: Patients whose asthma is not adequately controlled despite treatment with a 
  combination of high dose inhaled corticosteroids and long-acting bronchodilators pose a 
major clinical challenge and an important health care problem. Patients with severe refractory 
disease often require regular oral corticosteroid use with an increased risk of steroid-related 
adverse events. Alternatively, immunomodulatory and biologic therapies may be considered, 
but they show wide variation in efficacy across studies thus limiting their generalizability. 
Managing asthma that is refractory to standard treatment requires a systematic approach to 
evaluate   adherence, ensure a correct diagnosis, and identify coexisting disorders and trigger 
factors. In future,   phenotyping of patients with severe refractory asthma will also become an 
  important element of this systematic approach, because it could be of help in guiding and tailor-
ing   treatments. Here, we propose a pragmatic management approach in diagnosing and treating 
this challenging subset of asthmatic patients.
Keywords: severe asthma, corticosteroids, immunological modifiers, steroid-sparing, 
  anti-TNF-α drugs, omalizumab, mepolizumab, daclizumab, bronchial thermoplasty
Introduction
Asthma is a common chronic inflammatory disorder of the airways characterized by 
bronchial hyperresponsiveness (BHR), reversible airflow limitation, and   recurrent 
  episodes of wheezing, shortness of breath, chest tightness, and cough. Asthma is a 
complex syndrome with many clinical and inflammatory phenotypes.1 Various   factors 
like the environment, genetics, levels of hygiene, and atopic status play a role in the 
development and progression of asthma phenotypes. Most patients with asthma have 
mild-to-moderate disease and can be easily controlled by regular use of inhaled corti-
costeroids (ICS) combined with short-acting inhaled β2-agonists for relief of symptoms. 
However, for some patients, asthma continues to be poorly controlled in terms of ongo-
ing symptoms, frequent exacerbations, persistent and variable airway obstruction, and 
frequent requirement for β2-agonists despite aggressive treatment. Severe or refractory 
disease remains a frustrating problem for both patients and the clinicians treating them 
with disproportionately high health-related costs.2–5 A number of clinical definitions have 
been proposed through national and international   guidelines, working groups, which 
incorporate lung function, exacerbations, and use of high-dose corticosteroids.2,6–8 Of 
note, is that all these various criteria/guidelines are applicable when patients have had 
adherence and exacerbations fully addressed.9,10 Many   different terms have been used 
to describe this group of patients with   persisting symptoms and frequent exacerbations 
despite being treated with high-intensity   treatment for asthma.Journal of Asthma and Allergy 2010:3 submit your manuscript | www.dovepress.com
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The term problematic severe asthma should be used for 
all patients who remain uncontrolled despite prescription 
of high-intensity asthma treatment.11 Apart from patients 
with true severe refractory asthma (SRA), this group also 
includes patients with “difficult asthma,” that is uncontrolled 
asthma for reasons such as persistently poor compliance, 
psychosocial factors, or persistent environmental exposure 
to allergens or toxic substances. It also includes patients 
who have mild – moderate disease that is aggravated by 
comorbidities such as chronic rhinosinusitis, reflux disease, 
or obesity. The term severe refractory asthma should be 
reserved for those patients with severe disease who have 
been under the care of an asthma specialist for .6 months, 
and still have poor asthma control or frequent exacerbations 
despite   taking high-dose ICS combined with long-acting 
β2-agonists (LABA) or any other controller medication or 
for those who can only maintain adequate control by taking 
oral corticosteroids (OCSs) on a continuous basis, and are 
thereby at risk of serious adverse effects.
Current asthma guidelines offer little alternatives to OCS 
for the management of the challenging patient with SRA 
and these include high-dose ICS combined with LABA, 
  methlyxanthines, antileukotrienes, and omalizumab.12 
  However, these medications are of variable efficacy and use-
ful only in a limited subset of patients.13 In actual fact, a large 
number of patients with SRA are on frequent, intermittent, 
or continuous courses of oral prednisolone (in addition to 
high-dose ICS combined with LABA) with an increased risk 
of steroid-related adverse events.14
Here, we review the practical aspects of patients’ manage-
ment to make sure that patients “labeled” as having SRA truly 
have SRA, and if so then to discuss the use of add-on thera-
pies both established and novel, including immunological 
modifiers and biological agents so to propose to   physicians a 
pragmatic management approach in diagnosing and treating 
this challenging subset of asthmatic patients.
Adherence to medication
Before developing a roadmap in aid of a pragmatic approach 
in diagnosing and caring for this troublesome condition, 
it is important to make sure that the issue of adherence is 
  adequately addressed. Poor asthma control can result from poor 
  adherence to treatment;15,16 hence, once the diagnosis of SRA 
is confirmed then the priority would be exclude compliance to 
medication as a cause of ongoing symptoms. Detecting poor 
adherence to medications can be difficult, especially in the 
busy clinical settings. Ways of checking for adherence may 
include   collection of repeat prescriptions or the   measurement 
of serum   prednisolone and   cortisol levels in patients on OCS.17 
It has been reported in a study that 50% of patients on OCS 
had low serum levels   concentrations of   prednisolone and 
cortisol.18 Although, this seems   controversial, it   signifies 
that despite having significant symptoms, these patients 
with SRA are noncompliant with their medication. Hence, 
  better   communication between the patient and   physician, and 
patient education is important.19 Frequent consultations and 
patient-centered approaches may be useful ways of   improving 
compliance.
There could be a number of reasons for which the patient 
may not be adhering to their medications: their perception 
that the treatment is ineffective, delayed effectiveness of 
medications (ICS), lack of understanding, poor inhaler 
  technique, antipathy towards asthma and its treatment, 
  monetary reasons, psychosocial causes and attention seeking, 
stress, and forgetfulness.17
Evaluation of severe  
refractory asthma
There are no validated algorithms to substantiate the most 
useful approach to the evaluation of the patient with   suspected 
SRA, but some have been suggested.9,10,17 A rational method 
would involve 3 main aspects:
(a)	confirmation of severe asthma
(b)	evaluation of other conditions, coexisting conditions and 
trigger factors
(c)	evaluation of the severe asthma subphenotype.
(a) Confirmation of severe asthma
Many aspects need to be considered prior to prescribing add-on 
treatments and incremental doses of ICS and OCS to patients 
thought to have SRA. It is necessary to ascertain whether they 
genuinely have severe asthma (Figure 1). Hence, first one 
needs to obtain a detailed history from the patient including 
details of respiratory symptoms (including chest tightness, 
wheezing, cough, night and exercise/  environmental-related 
symptoms), the original diagnosis (including who, when, 
how, and previous investigations), asthma-related morbidity 
(intensive care/hospital   admissions, hospital length of stay, 
number of exacerbations per year, exacerbating   factors, and 
severity of symptoms), associated comorbidities (including 
chronic rhinosinusitis disease, cardiac conditions, gastrooe-
sophageal reflux, obesity, and psychological factors), family 
history, smoking history, and current medication (including 
compliance, technique, intolerance to medications, and new 
medications). Second, a thorough physical examination of 
both respiratory and cardiovascular systems is essential. Third, Journal of Asthma and Allergy 2010:3 submit your manuscript | www.dovepress.com
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previous investigations, in particular full blood count, total 
immunoglobulin E (IgE), autoimmunity, pulmonary function 
tests, plain chest X-ray, and saturation   oximetry (or some-
times arterial blood gases) should be carefully reviewed and 
if necessary repeated. The pulmonary function tests should 
include actual and predicted values for forced   expiratory 
volume in 1 second (FEV1), forced vital capacity, and small 
airways (forced expiratory flow [FEF25–75]) to document the 
presence of airflow limitation. Simultaneous assessment 
of FEV1 reversibility to 400–800 µg inhaled salbutamol20 
is   helpful. In addition, fall in FEV1 when   tapering steroid 
  treatment can be also used to document variable airflow 
limitation and steroid dependency.
Occasionally, reversibility testing may not be   conclusive and 
confirmatory tests including bronchial provocation   challenges21 
(using methacholine or mannitol22), exhaled nitric oxide mea-
surements, and exercise testing may be required. In patients 
without positive challenge test with bronchial   provocation, 
alternative diagnosis(es) should be considered. Further, more 
directed investigations to exclude other conditions should be 
considered to alternative diagnosis(es) be suspected (see later); 
these may be in addition to or instead of asthma.
(b) evaluation of other conditions, 
coexisting conditions and trigger factors
(i) evaluation of other conditions (pseudoasthma)
Other conditions should be taken in consideration in the 
  differential diagnosis of SRA (Figure 1). A diagnostic work-up 
of SRA assumes that these conditions should be excluded 
systematically1,10 Taking a detailed history may arouse 
  suspicion of other conditions and   appropriate   investigations 
can confirm or exclude these. These   conditions and appropri-
ate investigations include the following (Table 1).
Bronchiectasis
Taking a detailed history of childhood and partially trea-
ted respiratory infections as well as a history of cough, 
  breathlessness, and sputum production may direct you to 
Unremitting asthma symptoms and/or frequent exacerbations despite high dose ICS & LABA (+/−anti-leukotrienes, +/−theophylline), frequent
use of OCS and healthcare utilization (A&E attendances, Medical/ITU admissions, GP visits)
Medical History (diagnosis, allergies, best PEF, ITU admission, A&E attendances)
Investigations (CXR, pulmonary function tests, reversibility, serum IgE levels, SPT. If non-
diagnostic consider methacholine/histamine challenge, NO studies and/or sputum induction)
Physical Examination (PEF, pulse oximetry {ABG if SaO2 <92%}, respiratory rate, chest examination, pulse)
Consider
–  Self-management plan
–  Frequent follow-up  visits
Pseudo-asthma Conditions Co-morbidities + Asthma Triggers
Present Present
–  Confirm diagnosis with appropriate investigation & 
    treat
Check inhalation technique, spacer 
use & compliance with medications
1.  Taper OCS to lowest possible dose.
2.  Consider adding in immunomodulators as steroid-sparing agents.
3.  If adverse events or no improvement consider biological agents/bronchial thermoplasty.
4.  Regular follow-up and treatment of potential events related to OCS treatment of other therapies administered.
Yes Yes
Good
Poor
Yes
No
Course of OCS 
(1 mg/kg/day
prednisolone)
Clinical Response
No
–  Confirm diagnosis with appropriate investigation & 
    treat
–  Identify triggers +  trigger avoidance management
Figure 1 Algorithm summarizing the strategies and mechanisms of managing subjects with suspected severe refractory asthma (SRA).
Abbreviations: iCS, inhaled corticosteroids; LABA, long-acting beta 2 (β2)-agonists; OCS, oral corticosteroids; A&e, accident and emergency; eD, emergency department; 
ITU, intensive therapy unit; GP, general practitioner; PEF, peak expiratory flow; ABG, arterial blood gas; CXR, chest X-ray; IgE, immunoglobulin E; SPT, skin prick testing; 
NO, nitric oxide.Journal of Asthma and Allergy 2010:3 submit your manuscript | www.dovepress.com
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Allergic bronchopulmonary aspergillosis
Care must be taken to exclude allergic bronchopulmonary 
aspergillosis (ABPA) by investigating for specific criteria 
for diagnosis, some of which include elevated total IgE and 
specific IgE and/or IgG to Aspergillus fumigatus, positive 
skin prick test to A fumigatus, and central bronchiectasis 
on HRCT.24 Delay in diagnosis and treatment may lead to 
permanent damage to the lungs.
Churg–Strauss vasculitis
The early stage of Churg–Strauss syndrome exhibits substantial 
overlap with severe asthma, which makes diagnosis difficult. 
However, unlike severe asthma, Churg–Strauss syndrome 
may progress into a life-threatening systemic   vasculitis, with 
vascular and extravascular granulomatosis. A diagnosis of 
Churg–Strauss vasculitis may difficult to tease out as often it 
manifests a number of overlapping symptoms involving several 
organ systems.25 Laboratory abnormalities include anemia, 
persistent eosinophilia, raised erythrocyte sedimentation rate, 
and positive antineutrophil   cytoplasmic antibody (in about 
30%–50% of cases).   Diagnostic   confirmation can be obtained 
by biopsy of the lung or other clinically affected tissues. Like 
ABPA, prompt diagnosis and   treatment are important to avoid 
irreversible sequel to the lungs. Treatment often includes high-
dose OCS and cytotoxic/immunosuppressive therapy.
Vocal cord dysfunction
Vocal cord dysfunction may mimic SRA, presenting with 
wheezing, cough and breathlessness that is episodic, begin-
ning and remitting abruptly, and nonresponsive to asthma 
treatments.26 Of note, in these patients expiratory loop and 
flows are preserved, but inspiratory loop is flattened reflecting 
reduced flow due to vocal cords partially   opposing   during 
inspiration, causing partial flow obstruction.   Diagnosis 
is made by direct visualization of the vocal cords by 
  laryngoscopy when the patient is symptomatic.27
Cardiac disease
Occasionally, congestive heart failure may present with a 
cardiac wheeze and masquerade SRA.28 On   examination, 
patients may present with tachypnea, crackles on   auscultation 
  (normally at the bases), displaced apex beat, elevated   jugular 
venous pressure, and peripheral edema depending on the type 
of heart failure. Occasionally, they may also present with 
cyanosis, gallop rhythm, pleural effusions, murmurs, etc. 
Electrocardiograms, cardiopulmonary exercise   testing, 
echocardiography, and/or cardiac angiography may be   helpful 
to identify any cardiac causes. If a cardiac cause is proved, 
Table 1 examples of diagnostic tools that can assist in distinguishing 
severe asthma from alternative conditions that may mimic asthma
Suspected alternative diagnosis Diagnostic test
intrabronchial obstruction Bronchoscopy
vocal cord dysfunction Laryngoscopy during attack
Dysfunctional breathing/panic attacks Blood gases during attack  
Hyperventilation 
provocation test
Recurrent microaspiration Proximal esophageal pH  
measurement  
Bile salts in bronchoalveolar 
lavage fluid
CF Sweat test
ABPA Aspergillus ige/precipitins/
sputum culture
emphysema 
Hypersensitivity pneumonitis  
Bronchiectasis (including ABPA and CF)
High resolution CT-scan
Recurrent pulmonary embolism  
Pulmonary arterial hypertension
D-dimer, doppler US of 
the limbs, CT pulmonary 
angiography, right heart 
catheterization
Bronchiolitis
Sarcoidosis
Transbronchial or 
thoracoscopic lung biopsy  
Biopsy of affected organ(s)
Churg–Strauss syndrome ANCA
Abbreviations: ABPA, allergic bronchopulmonary aspergillosis; CF, cystic fibrosis; IgE, 
immunoglobulin e; CT, computed tomography; US, ultrasound.
think of bronchiectasis. On examination, patients may most 
  commonly have crackles, rhonchi, wheezing, and inspiratory 
squeaks on auscultation. Occasionally, they may also present 
with digital clubbing, cyanosis, plethora, wasting, and weight 
loss. A high resolution computed tomography (HRCT) scan 
may help to diagnose this.
Interstitial lung disease
Not only a history of progressive breathlessness, but also appro-
priate history of medication and examination should cause 
suspicion of interstitial lung disease (ILD). On   examination, 
patients may present with digital clubbing, cyanosis, weight 
loss, wheezing, end inspiratory fine   crepitations, desaturation 
and breathlessness on exertion, as well as signs of the disease 
causing the ILD. An HRCT would be helpful diagnostically.
Chronic obstructive pulmonary disease
Diagnostic confusion is common between SRA and chronic 
obstructive pulmonary disease (COPD),   particularly 
in the middle-aged patient presenting with cough and 
mild   exertional dyspnea who also smokes cigarettes.23 
  Differentiating between SRA and COPD can be achieved 
by taking careful patient history and by looking at the 
  appropriate investigations, but neither should be used in 
isolation to differentiate them.Journal of Asthma and Allergy 2010:3 submit your manuscript | www.dovepress.com
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treatment would obviously be directed towards this and not 
increase antiasthma medications.
(ii) evaluation of coexisting conditions  
and trigger factors
It has been reported that other conditions can coexist along-
side severe asthma, and these may present, if untreated, with 
asthma-like symptoms.18,28 Hence, coexisting conditions need 
to be carefully identified and managed, as it may improve the 
patients’ symptoms and prevent further escalation of asthma 
medications (Figure 1). Remember, taking a detailed history 
may arouse suspicion other comorbidities or appropriate 
investigations confirm these. Some of these conditions and 
appropriate investigations are as follows.
Chronic rhinosinusitis
Chronic rhinosinusitis is frequently associated with SRA29,30 
and nasal polyposis is often related to aspirin (and/or non-
steroidal anti-inflammatory drugs [NSAIDs]) intolerance and 
a more severe asthma phenotype.31–33 Symptoms of rhinosinus-
itis include nasal congestion and obstruction, purulent nasal 
discharge, maxillary tooth discomfort, and facial pain or pres-
sure. Other signs and symptoms include fever, fatigue, cough, 
hyposmia or anosmia, ear pressure or fullness, headache, and 
halitosis. Diagnosis is confirmed by nasal endoscopy and com-
puted tomography-imaging of the sinuses. Medical (nasal and/
or systemic corticosteroids, immunotherapy, antihistamines, 
and antibiotics) or   surgical treatment of upper airway disease 
can improve asthma control. Therefore, patients with severe 
asthma should be systematically evaluated and treated for 
rhinosinusitis with or without nasal polyps (Table 2).
Gastroesophageal reflux disease
Gastroesophageal reflux disease (GERD) is common among 
patients with asthma, but often causes mild or no symptoms. 
Although it has been suggested as a pathophysiological link 
between gastroesophageal reflux and asthma, the exact rela-
tionship between the 2 conditions has not been fully estab-
lished.34 GERD may be suspected in patients with heartburn, 
regurgitation, and dysphagia. Less common symptoms include 
odynophagia, excessive salivation,   nausea, chest pain, chronic 
cough, laryngitis, erosion of dental enamel, and hypersensitiv-
ity. Although detection of GERD is   ideally obtained by 24-hour 
pH monitoring, many   physicians prefer to give an empiric ther-
apy trial of $3 months with high-dose proton pump inhibitors 
(PPI; Table 2). PPIs have shown to reduce asthma symptoms in 
some studies,35,36 but not in others.37,38 Treatment with PPI does 
not improve asthma   control and is unlikely to be the cause of 
the poorly controlled asthma.38 No specific studies have been 
carried out in the subset of patients with SRA.
Psychosocial factors
Subjects with asthma are more likely to be treated for a mental 
health problem (depression, anxiety, and panic disorders) and 
demonstrate more negative social outcomes.39 This is more so if 
the patient has severe disease or has had a life-threatening epi-
sode.17,40 In addition, anxiety disorders41 and acutely negative 
affective disorders42 have also been shown to have an impact 
on asthma. In an open-labeled study of 75 patients with SRA, it 
was reported that 33 had a psychiatric element to their asthma 
and in 10 of those this was thought to be “major.”18 Specialist 
help from a psychiatrist is needed to establish the correct diag-
nosis and its significance. However, it is still controversial as 
to whether treatment of the psychological condition may lead 
to an overall improvement in asthma control and severity.
Drugs
Various drugs can provoke an asthma attack or worsening 
asthma symptoms. Some of these include β-blockers, aspi-
rin, NSAIDs,18 angiotensin converting enzyme inhibitors, 
Table 2 Diagnostic tools and treatment of most common comorbidities in severe asthma
Comorbid condition Diagnostic test Treatment
Gastroesophageal reflux  3 months empiric therapy trial with  
high dose PPi or esophageal pH testing
Lifestyle modifications  
PPis  
Surgery
Obesity with or without  
obstructive sleep apnea syndrome
BMi ± polysomnography weight control  
Positive airway pressure  
Oral appliances  
Surgery
Sinus disease CT-scan Rhinoscopy (for sinus discharge) Nasal irrigation with saline  
corticosteroid spray 
corticosteroid drops  
Antibiotics  
surgery
Abbreviations: PPi, proton pump inhibitors; BMi, body mass index; CT, computed tomography.Journal of Asthma and Allergy 2010:3 submit your manuscript | www.dovepress.com
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and estrogens. Likewise, food intolerances can have similar 
effects on asthma control.
Smoking
Cigarette smoking has multiple negative effects on asthma. 
Accelerated decline in lung function over time is present in 
asthmatic individuals who smoke.43 Smokers with asthma 
are more symptomatic and have more severe and frequent 
exacerbations and emergency care needs.44 Asthma mortality 
is greater among asthmatics who smoke cigarettes compared 
with asthmatics who do not smoke.45 In addition, asthmatic 
patients who smoke appear to have a reduced therapeutic 
response to both inhaled and OCSs.46,47 Last but not least, 
recent research has shown that cigarette smoking is an impor-
tant independent risk factor for new onset asthma in allergic 
individuals.48 Hence, smoking cessation is also critical in the 
management of the patient with SRA who smokes.
Allergens and trigger factors
Unusual asthma triggers is a vital component that requires 
addressing and may be helpful in managing the patient.   Triggers 
could be exogenous or endogenous, the latter of which can be 
related to the comorbidities discussed early, such as respiratory 
infections, gastroesophageal reflux,   psychological triggers, etc. 
Exogenous factors include   allergens49 or   occupational/domestic 
sensitizers that may boost the inflammatory response of the 
underlying asthma and enhance BHR, thus contributing to the 
severe asthma phenotype.1 A recent study has reported that 
specific work environments are associated with the develop-
ment of severe asthma.50   Dissecting out the individual role 
of exogenous or endogenous factors requires a high level of 
suspicion and great skills in history taking.
Obesity
The European Network for Understanding Mechanisms 
of Severe Asthma study has reported that patients with 
more severe disease are women with a component of irre-
versible airflow obstruction, neutrophilic inflammation, 
reduced atopy, and with a larger body mass index.2 There 
is also accumulating evidence that obese patients have an 
increased risk of developing asthma.51 Although asthma 
and obesity are frequently associated, the contribution of 
obesity to severe asthma as well as the mechanisms respon-
sible for this relationship are not fully clarified. Although 
morbid obesity is positively associated with reduced lung 
volumes and the presence of comorbid aggravating factors, 
  including gastric reflux, obstructive sleep apnea syndrome, 
and   psychological factors,52 the overall strength of the 
  relationship between obesity and severe asthma appears to 
be modest53 (Table 2). Although the evidence that weight 
control interventions are associated with improvements in 
asthma control remains controversial,54,55 weight reduction 
should be strongly encouraged anyhow.
(c) evaluation of severe asthma 
subphenotype
By systematically addressing conditions and factors accord-
ing to the diagnostic work-up illustrated earlier, it is possible 
to define patients with truly SRA. However, this subgroup is 
far from being homogeneous and may be further subdivided 
into different phenotypes. Phenotyping of patients with SRA 
is becoming increasingly important because it may help to 
guide current and possibly future treatments. However, the 
true significance of phenotyping SRA can be firmly estab-
lished only when detailed characterization of hundreds of 
patients will be completed and analyzed, as proposed in the 
newly established pan-European consortium Unbiased Bio-
markers for the Prediction of Respiratory Disease Outcome 
funded by the Innovative Medicines Initiative in its program 
Understanding Severe Asthma.56
In clinical practice, most patients with severe asthma are 
by and large belonging to 3 categories: (1) those   suffering 
from frequent severe exacerbations with relatively stable 
episodes between exacerbations (exacerbation prone asthma), 
(2) those who develop irreversible airflow obstruction 
(asthma with fixed airflow obstruction), and (3) those who 
depend on systemic corticosteroids for daily control of their 
asthma (steroid-dependent asthma).10
From a pathological point of view at least 2 phenotypes 
of severe asthma have been proposed, each associated with 
distinct clinical and pathophysiological characteristics. These 
subtypes include the persistent eosinophilic and noneosino-
philic forms of severe asthma.57
Management of severe  
refractory asthma
Treatment of SRA remains highly problematic and   regular 
systemic corticosteroids are often needed to minimize symp-
toms. Hence, SRA patients not only are at risk of dying from 
their asthma, but also from the comorbidities associated 
with the excessive steroid use.7,58 Patients with such severe 
disease that is unremitting to guideline-based management 
may be better looked after at dedicated clinics where patients 
would be assessed for alternative diagnoses and comor-
bidities, adequately phenotyped using more   specialized 
  investigative   methods, and optimally managed with the best Journal of Asthma and Allergy 2010:3 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
49
Severe refractory asthma
possible   treatments available, and where patients may also 
have facilitated access to a multidisciplinary team (physicians, 
ear, nose, and throat specialists, psychologists, pharmacists, 
and specialist nurses).17 However, only a few tertiary asthma 
centers are available.59
Optimal treatment of SRA should be aimed at achieving 
the best possible asthma control and quality of life (Qol) 
with the least dose of medication (particularly systemic corti-
costeroids). The choice and formulation of therapeutic agents 
to be used should be dictated by disease severity, therapeutic 
response, patient’s comorbidities and preferences, as well as 
on the agents’ adverse event profile. These include:
(a)	standard therapies
(b)	immunomodulatory agents
(c)	biological and other novel therapies.
Standard therapies
Standard treatment for patients with severe asthma includes 
high-dose ICS ($1,200 µg/day or equivalent of beclom-
ethasone) in combination with a LABA. There are a number 
of combined inhalers in the market that can also used with 
a spacer device.6 Therefore, if a patient has not been on 
high-dose ICS (along with LABA), a trial is certainly war-
ranted.60 More recently, there have been suggestions that an 
ICS with smaller particle size for more distal penetration of 
the airways to improve inflammation in smaller airways has 
been proposed, but its efficacy has yet to be evaluated in 
SRA.9 Although it has been reported that the use of LABA 
may reduce the dose of ICS by 57%,61 they may not be as 
efficacious in patients with SRA than in moderate persistent 
asthma.62,63 Leukotriene antagonists may be beneficial in 
some patients with severe asthma, especially those with 
aspirin sensitivity.2,64 Other drugs used in which reports 
of improvements in patients with SRA, but not assessed 
by randomized clinical trials, include anticholinergics,65,66 
theophyllines,67,68 and intravenous (IV) magnesium.69,70 
Hence, a trial of these agents may prove useful.
Inspite of using these additional therapies, there is a sub-
group of patients with severe unremitting disease who require 
high doses of OCS ($30 mg/day) on a daily basis to attain 
an adequate level of control of their symptoms and QoL. 
This subgroup of patients often exhibits   deterioration of their 
asthma symptoms as soon as the dose of   corticosteroids is 
tapered. Hence, reasonable control of their asthma can only be 
achieved at the cost of significant morbidity (eg, osteoporosis, 
diabetes, hypertension, cataract formation, gastrointestinal 
(GI) bleeding, myopathy, adrenal insufficiency, susceptibility 
to infections, weight gain, and skin thinning).71,72
immunomodulatory drugs
To curtail the necessity of prolonged OCS use and the adverse 
effects associated, a trial with immunomodulatory drugs 
may be an option. Some of the agents that can be   considered 
include methotrexate, cyclosporine A, and macrolide anti-
bacterials.13 Other agents have been investigated but are not 
commonly used and include azathioprine, gold, and IV IGs.13 
We shall discuss the former 3 agents as they have been more 
commonly tried as corticosteroid-sparing agents in severe 
asthma (see Table 3 for summary).
Methotrexate
Methotrexate is a folic acid inhibitor, but at low doses has 
immunosuppressive and anti-inflammatory   properties.73 
  Methotrexate is the most clinically investigated immuno-
logical agents in severe asthma. In total, there have been 
11   well-conducted clinical trials published in the literature to 
evaluate the efficacy and safety of methotrexate in SRA.13 The 
trials involved the use of methotrexate administered orally at 
dose of 7.5–30 mg on a weekly basis for a period between 12 
and 24 weeks in patients who were mostly taking .10 mg of 
prednisolone daily. Some of them had run-in periods and were 
Table 3 Summary of evidence of efficacy of the immunomodula-
tory, biological, and other therapies in severe refractory asthma
Agent Evidence for efficacy 
(Reference in text)
Study type
Methotrexate Trigg et al76 PCC
Hedman et al75 PCC
Comet et al74 DBPC
Domingo et al79 OS
Cyclosporine A Lock et al87 DBPC
Nizankowska et al88 DBPC
Alexander et al89 PCC
Macrolides  
  Troleadomycin  
 
  Clarithromycin
Ball et al99 DBPC
Kamada et al100 DBPC
Nelson et al101 DBPC
Garey et al102 CS
Gotfried et al103 DBPC
Simpson et al104 DBPC
Omalizumab walker et al111 CR
Anti-TNF-α therapy 
  etanercept 
 
  Golimumab
Berry et al123 PCC
Howarth et al124 OS
Morjaria et al125 DBPC
wenzel et al126 DBPC
Mepolizumab (anti-iL5) Haldar et al134 DBPC
Daclizumab (anti-CD25) Busse et al140 DBPC
Bronchial thermoplasty Cox et al145 OS
Cox et al146 DBPC
Pavord et al147 DBPC
Castro et al148 DBPC
Abbreviations:  PCC,  placebo-controlled  crossover  study;  DBPC,  double-blind 
placebo-controlled study; OS, observational study; CS, case series; CR, cochrane 
review; TNF, tumor necrosis factor; iL, interleukin.Journal of Asthma and Allergy 2010:3 submit your manuscript | www.dovepress.com
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either placebo-controlled crossover (PCC) or double-blind 
placebo-controlled studies (DBPC). Only one of the studies 
had patients on methotrexate for a period of 12 months.74 Of 
all the studies, the 3 larger ones showed that the administra-
tion of methotrexate had a significant reduction in the OCS 
dose.74–76 None-life-threatening adverse events that were tran-
sient and reversible on stopping methotrexate administration 
including abnormal liver function tests, GI symptoms, oral 
ulcers, and stomatitis were noted. Of note, in 2 separate pro-
spective open-labeled extension studies for up to 28 weeks, 
oral methotrexate at 15 mg weekly were reported to result in 
a significant OCS dose reduction, and in fact more than half 
of the patients came off their OCS completely.77,78 In addi-
tion, in a large case series of patient with SRA treated with 
low dose methotrexate for up to 12 years it has been shown 
a substantial, safe decrease in OCS (OCSs were withdrawn 
completely in 59% of patients).79 Taken together, these find-
ings show that prolonged administration of methotrexate 
will be necessary to achieve significant OCS reduction or to 
wean off OCS completely.
Three meta-analyses have been published in the lit-
erature on methotrexate in SRA of the a number of the 
11 studies conducted showing a small but significant OCS 
dose   reduction with use of methotrexate.80–82 Also, no other 
subjective or objective parameters have been noted to be 
significantly altered with the administration of methotrexate. 
Although there were no predicting factors in the “responders,” 
these studies have shown that there are some subgroups 
of SRA patients who have benefited from the use of oral 
  methotrexate. Hence, as in the treatment of rheumatological 
and   dermatological conditions, the risk–benefit profile of 
methotrexate is preferable to that of the long-term use of OCS 
at doses .10 mg/day; thus, we recommend that methotrexate 
should be the first choice of steroid-sparing immunomodula-
tor therapy for patients with SRA.
Cyclosporine A
Cyclosporine A works by inhibiting the activation of T cells. 
T cells have been implicated in the pathogenesis of asthma 
and hence the drive to investigate its efficacy in asthma.83–86 
To date, there have been 3 published studies of the use of 
cyclosporine A at a dose of 5 mg/kg/day in SRA patients on 
a mean dose of .8.5 mg/day of prednisolone in the   literature 
(2 DBPC87,88 and 1 PCC89) for a period of 12–36 weeks. 
Among the 3 studies conducted, there were significant 
improvements in lung function, symptom scores, and reliever 
use; however, all 3 studies reported a significant reduction 
in OCS dose in the patients. Although in the conducted 
studies only minor adverse events of mild renal impairment, 
worsening of preexisting hypertension, paraesthesia, tremor, 
headaches, flu-like illness, and increased hypertrichosis were 
noted, these reversed on stopping the cyclosporine A.87–91 
Notably, there is always the dose-dependent nephrotoxicity 
concern based on the experience of transplant literature.
A meta-analysis of 3 studies using cyclosporine A in SRA 
has reported that the use of cyclosporine A is associated with 
a minor reduction in the OCS dose in these patients,92 but 
this is on the background of safety concerns of worsening 
hypertension and renal function. Furthermore, although we 
do not have any long-term studies in SRA, long-term use in 
other chronic inflammatory conditions such as rheumatoid 
arthritis (RA) and ulcerative colitis (UC) are burdened by sub-
stantial failure rates.93,94 Hence, not only do patients require 
close monitoring but also the risk of failure with cyclosporine 
A. With this in mind, future studies should be conducted with 
the use of newer cyclosporine A analogs, tacrolimus, and 
pimecrolimus, which have better safety profiles and more 
efficacious in corticosteroid-resistant conditions.
Macrolide antibacterials
Originally, macrolides (eg, troleadomycin) have been used 
in SRA, not for their antibacterial properties but for their 
steroid-sparing effects.95,96 Important benefits have also been 
noted with newer macrolides based on their anti-  inflammatory 
effects.97,98 Three DBPC studies99–101 have looked into the 
safety and efficacy of troleadomycin in patients with OCS-
dependent asthma, of which 2 were small and conducted in 
children.99,100 These latter 2 small studies reported substantial 
OCS dose reduction use and airway hyperresponsiveness 
(AHR).99,100 In the larger study that spanned 12 months, 75 
SRA patients on OCS were recruited and reported in those 
that completed the study that there was a significant reduction 
in OCS daily use; however, this was not associated with a 
reduction in the number of emergency department (ED) atten-
dance and admissions, asthma control, and AHR.101 Newer 
macrolides have been used demonstrating not only similar 
reductions in daily OCS use or weaning off OCS completely, 
but also airway inflammation and subjective parameters.102–104 
Troleadomycin, with its steroid metabolism activity on the 
cytochrome P450 complex was associated with not only 
increased the steroid-related adverse events, but also direct 
events such as GI symptoms and hepatotoxicity   ranging 
from transient liver enzyme abnormalities to cholestatic 
jaundice; hence, its use has been discontinued. However, 
the use of clarithromycin has not been associated with any 
major adverse events in the published literature.Journal of Asthma and Allergy 2010:3 submit your manuscript | www.dovepress.com
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Although initial data on the use of clarithromycin show 
that there is some benefit in the use of macrolides in SRA, 
more robust, well-conducted DBPC studies are needed to 
evaluate their true value.
Biologics and other therapies
Due to the refractoriness to OCS and/or immunomodulators, 
or adverse events to the latter novel strategies have been devel-
oped to evaluate alternative therapies in these SRA patients. 
These may be useful in a steroid-sparing or steroid-replacement 
role. These include the licensed omalizumab, and other drugs 
that have not been so efficacious or safe, and others with only 
small DBPC trial data (see Table 3 for summary).
Omalizumab
IgE has central pathophysiological role in the development 
of allergic conditions by enhancing dendritic cell allergen 
uptake, and activation and release of inflammatory mediators 
by mast cells and basophils.105,106 Omalizumab is a humanized 
IgE-specific monoclonal antibody that prevents   interaction 
of IgE to FcεR1 receptors on effector cells.107,108 Early 
pharmacodynamic studies have reported that omalizumab 
reduces inflammation, AHR, and allergen-induced airway 
and skin tests.109,110
There have been 6 large DBPC studies, evaluating over 
2,500 patients, that have been conducted to assess the safety 
and efficacy of omalizumab in severe atopic asthmatics who 
had persisting symptoms despite optimum treatment.111 
Omalizumab is administered either 2-weekly or 4-weekly 
depending on the weight and IgE levels, in patients with an 
IgE level between 30–700 IU/ml over 25–52 weeks in the 
various studies. Pooled analyses of the studies have reported 
that the addition of omalizumab has beneficial improve-
ments in the reduction of exacerbations, reduction in ED 
attendances, asthma-related QoL, asthma symptoms, lung 
function as well as reduction in steroid reliever usage.111–115 
Also reported was that the therapeutic response of omali-
zumab is best assessed at 16 weeks after initiation to justify 
its continuation. In addition, compared with placebo, patients 
treated with omalizumab did not have significantly more 
adverse events. Most of the adverse events were minor 
such as headaches, cough, GI symptoms, urticaria, and 
injection-site reactions.116 There have been postmarketing 
reviews suggesting that there are slightly increased number 
of anaphylactic and anaphylactoid reactions, malignant 
neoplasms, and helminth infections in patients treated with 
omalizumab and that caution and vigilance of these need to 
be in the clinicians mind.105,116,117
The number of patients with severe atopic asthma is small 
and it is only in around two-thirds of these that omalizumab 
may be effective and hence the 16-week and regular assess-
ment of its efficacy and safety need to be in reviewed, but 
also that the large majority of SRA patients are nonatopic 
and hence the use of omalizumab may be a limited option. 
Besides, the use of omalizumab is not licensed in severely 
atopic patients and its cost is a limiting feature. In England, 
the National Institute of Clinical Excellence advises the 
use of omalizumab in patients who have had 2 or more ED 
attendances and/or hospital admission due to lack of control 
of their asthma despite optimal therapy.105 Other criteria 
include atopy to at least a common allergen, and compliance 
and adherence to asthma medications.
Anti-tumor necrosis factor alpha drugs
Anti-tumor necrosis factor alpha (TNF-α) is a multifunc-
tional proinflammatory TH1 cytokine. Corticosteroids fail 
to reduce TNF-α and TH1 cytokines in asthmatic airways 
and hence explain the lack of steroid efficacy in these severe 
asthma patients.118 TNF-α has been implicated in the vari-
ous pathological processes of asthma.119 Hence, the trial of 
anti-TNF-α agents in SRA was considered. Importantly, 
anti-TNF-α agents are widely used in other TH1-mediated 
chronic conditions such as RA, psoriasis, Crohn disease, and 
ankylosing spondylitis with good efficacy and safety.120
In mild and moderate asthma, anti-TNF-α treatment has 
proved to be noneffective.121,122 Two initial small studies of 
anti-TNF-α treatment, using the soluble receptor etanercept, 
showed that there were marked improvements in   subjective 
(asthma-related control and QoL) as well as objective 
(spirometry, peak flows, and AHR) measures of asthma and 
reduction in reliever medication use.123,124 More recent larger 
studies using etanercept125 and the monoclonal antibody, 
golimumab,126 have shown that there were minimal or no 
important changes in asthma measures. In fact, in the latter 
study the trial was terminated early due to the increased num-
ber of patients who developed solid malignancies and serious 
infections. Safety of anti-TNF-α agents comes mainly from 
studies of rheumatological conditions, including increased 
risk of malignancies, opportunistic infections and reactiva-
tion of tuberculosis, demyelination, and cardiac failure.119,127 
In the asthma studies besides the major adverse events noted 
in the golimumab study, only minor adverse events were 
noted including injection-site reactions, rashes, respiratory 
tract and asthma exacerbations, and headaches.122–125
The role of anti-TNF-α agents in severe asthma, alth  ough 
initially looked promising, were darkened by the outcomes of Journal of Asthma and Allergy 2010:3 submit your manuscript | www.dovepress.com
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the larger studies both in terms of efficacy and safety. Of note, 
there are floors in the larger studies including recruiting of 
milder patients, short treatment, and observation periods. 
It also seems that the soluble receptor, etanercept, is   associated 
with less severe adverse event and more efficacy.
However, in view the findings of anti-TNF-α agents are 
no longer under trial or use in severe asthma.
Mepolizumab (anti-iL-5)
Th2 cytokines, namely interleukin (IL)-4, 4, 5, 9, 13 
and granulocyte-macrophage colony-stimulating factor, 
are expressed in elevated amounts in severe disease.128 
  Monoclonal IL-5 antagonists have been studied in   varying 
severities of asthma, but have not shown any symptom or 
physiological improvements.129–132 However, they have shown 
significant reductions in circulating, bone marrow and airway 
eosinophilia, trend towards reduced risk of moderate/severe 
  exacerbations and attenuation of airway remodeling.131,133
In a recent study, Haldar et al134 studied the efficacy of 
anti-IL-5 therapy using mepolizumab in patients with eosino-
philic refractory asthma in DBPC fashion for 12 months. 
They reported a significant reduction in severe asthma 
exacerbations (primary outcome) and associated reductions 
in blood and sputum eosinophilia. Akin to previous studies, 
there were no significant changes in subjective or objective 
markers of asthma, but there was a small significant reduction 
in percentage (not actual) steroid usage in the mepolizumab 
group compared with placebo. The beneficial effects of 
mepolizumab have also been shown in another prednisolone 
withdrawal study in severe eosinophilic asthma.135 The use of 
mepolizumab was not associated with any significant major 
or minor adverse events compared with placebo.
These 2 studies show that in a small subgroup of patients 
with asthma who continue to have sputum eosinophilia even 
after treatment with OCS and high-dose ICS, treatment 
with mepolizumab may be effective in reducing asthma 
exacerbations, steroid use, and potential airway remodel-
ing; however, this needs to be confirmed in larger studies in 
patients within this specific subgroup.
Daclizumab (anti-CD25)
It is well known that airway inflammation in asthma involves 
T-cell activation. It has been reported that there are increased 
number of activated CD25+ T cells and increased levels of 
IL-2 and soluble (s) IL-2 receptor alpha chain (sCD25) found 
in the airways of patients with severe asthma.136–139   Following 
T-cell activation, cytokine generation and secretion may 
contribute to the initiation and potentiation of   inflammation 
along with the development of repair leading to airway 
  remodeling.138 Daclizumab is a humanized monoclonal 
antibody to alpha (CD25) subunit of the high-affinity IL-2 
receptor, inhibiting IL-2 binding and thus IL-2’s biological 
activity.
In a DBPC study to evaluate the efficacy and safety of 
daclizumab in moderate to severe patients with asthma, it was 
reported that there were small, but significant improvements 
in FEV1, daytime asthma symptoms, and prolonging of time 
to exacerbation in the patients on daclizumab compared with 
controls.140 Also, there was marked reduction in reliever use 
in favor of patients on daclizumab. Although there were no 
differences in mild and moderate adverse events between the 
2 study groups (upper respiratory tract infection, nasophar-
yngitis, nasal congestion, rash, and nausea), there were 
more patients with serious adverse events in the daclizumab 
group including anaphylactoid reaction, viral meningitis, 
  exacerbation of UC, and diabetics.
This small study demonstrates that daclizumab may have 
a role in asthma and further studies are needed to define its 
role as an add-on therapy.
Bronchial thermoplasty
An increase in airway smooth muscle (ASM) is thought to be 
an important factor in severe and fatal asthma.141,142 Bronchial 
thermoplasty (BT) is the delivery of controlled thermal energy 
to the airway wall during several bronchoscopy procedures. 
The application of BT to the airways is an innovative treat-
ment approach to reduce the bronchoconstrictor response in 
asthma. Preclinical studies have demonstrated that BT results 
in reduction of the ASM,143,144 and animal models have been 
associated with a long-lasting reduction in AHR.143
In a proof-of-concept study in 16 patients with mild-
to-moderate asthma, it was confirmed that BT results in an 
improvement in symptom-free days and peak expiratory flow 
(PEF) at 3 months, and an improvement in AHR with an asso-
ciated reduction in asthma symptoms and no adverse events 
for a period of 2 years.145 In the Asthma Intervention Research 
(AIR) trial, which was to assess the efficacy of BT in patients 
with moderate to severe asthma, it was observed that follow-
ing BT patients had significantly reduced mild exacerbations 
and use of reliever medication, improvement in morning PEF, 
asthma-related QoL, and control compared with controls.146 
Post hoc analysis suggested that the benefits were greatest in 
patients with more severe disease. Hence, in a smaller study 
(Research in Severe Asthma [RISA]) similarly designed to 
the AIR study, BT was administered in patients with severe 
asthma and showed similar improvements in outcomes to the Journal of Asthma and Allergy 2010:3 submit your manuscript | www.dovepress.com
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AIR study.147 In both studies (AIR and RISA), there were 
notable adverse effects of BT and lack of effect on AHR. 
The significant increased respiratory adverse effects included 
wheezing, cough, chest discomfort, dyspnoea, productive 
cough, and discolored sputum in the BT group compared with 
control. Although both these   studies showed improvement 
in asthma outcomes, there was   prudence of the high placebo 
effect. Thus another study, AIR2, was conducted in severe 
asthma patients in whom a sham procedure was conducted to 
overcome the placebo effect.148 At 6–12 months post-treatment, 
BT had a small, but significantly improved asthma-related 
QoL score compared with sham control. Of note, there are no 
differences between the 2 treatments in any of the secondary 
outcome measures, but safety assessments showed less (but 
nonsignificant) severe exacerbations and ED attendances in 
the BT group compared with the sham control group.
Overall, the AIR2 study has demonstrated disappointing 
outcomes for BT. Severe asthma has many phenotypes, and 
in which phenotype BT may be efficacious requires further 
work. Also, the risk–benefit ratio of BT in these patients with 
steroids refractory disease needs to be assessed.
Conclusion and the future
Managing asthma that is refractory to standard treatment 
requires a systematic approach to evaluate adherence, ensure 
a correct diagnosis, and identify coexisting disorders and trig-
ger factors. In future, phenotyping of patients with SRA will 
also become an important element of this systematic approach, 
because it could be of help in guiding and tailoring treatments.
Treatment of SRA remains highly problematic and 
regular systemic corticosteroids are often needed to mini-
mize symptoms. Despite the unquestionable beneficial role 
of systemic corticosteroids for most patients with SRA, 
they do not seem to be effective in every patient and they 
are associated with severe adverse side effects. Moreover, 
immunomodulatory and biologic therapies reportedly lack 
high levels of efficacy, show wide variation in success rates 
across studies, and are associated with adverse side effects.
Consequently, there is a compelling need for more 
effective drugs for these challenging patients. Identifying 
medications that reduce the need for systemic corticosteroids 
in patients with SRA should be a priority for the academic 
world and the pharmaceutical industry.
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